Report error Found 134 Enz. Inhib. hit(s) with all data for entry = 12883
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair
TargetMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase(Human)
Insilico Medicine IP
US Patent
Insilico Medicine IP
US Patent
Affinity DataIC50: 10nMAssay Description:Compound serial dilution is performed by Echo, and the final concentrations vary from 10 μM to 0.5 nM. This was filled by the addition of 5 μL/well o...More data for this Ligand-Target Pair

















































